IDEX (NYSE:IEX) reported fourth-quarter results that cleared Wall Street hurdles, fueled by robust demand for its mission-critical fluidics and life science components, though its initial 2026 outlook suggested a cautious start to the new year.
The Northbrook, Illinois-based manufacturer—well known for producing the Jaws of Life rescue tools—posted net income of $128.3 million, or $1.71 per share.
On an adjusted basis, earnings reached $2.10 per share, comfortably beating the $2.04 consensus estimate from analysts surveyed by Zacks Investment Research.
Revenue for the period rose to $899.1 million, surpassing the $881.6 million anticipated by the market, as the company benefited from momentum in its Health & Science Technologies (HST) segment.
Operational performance was bolstered by a 9.2% jump in HST sales, which offset a slight contraction in the Fire & Safety/Diversified Products unit.
The company's ability to maintain pricing power and manage supply chain costs resulted in an operating margin of 20.4%, an improvement from 19.2% in the prior-year period.
For the full year 2025, IDEX generated $483.2 million in profit on $3.46 billion in revenue.
Looking ahead, IDEX provided a forecast for the first quarter of 2026 with earnings expected between $1.73 and $1.78 per share.
For the full year 2026, the company projects a range of $8.15 to $8.35 per share.
While the midpoint of the full-year guidance aligns with current analyst models, the first-quarter outlook sits slightly below the $1.85 consensus, reflecting a conservative stance on near-term industrial volume recovery.